Tumor Biology

, Volume 35, Issue 11, pp 11229–11235 | Cite as

Vascular marker expression during the development of various types of gynaecological malignancy

  • Peter Urban
  • Miroslava Bilecova Rabajdova
  • Jan Varga
  • Peter Kruzliak
  • Viera Fialkovicova
  • Eva Durovcova
  • Maria Marekova
Research Article


Clinical diagnosis of gynaecological malignancies is usually successful in the advanced stages of the tumour, and this has a major impact on the success of therapy. Therefore, in the last few years, cancer research has tried to identify and characterise new biochemical and molecular markers needed as predictive indicators for the diagnosis of cancer. Our aim has been to search the molecular changes in gene expression of death receptor 6, glycoprotein M6B (Gpm6B) and genes associated with tumours of the female genital system. After isolation of messenger RNA (mRNA), transcription of mRNA into the cDNA was performed. The quantification of gene expression changes was detected using the reverse transcription polymerase chain reaction (RT-PCR) method. Analysis at the protein level was performed using the Western blot method. In both methods, we used actin as a housekeeping gene for normalisation. Numerical quantification of changes in expression and in the level of the specific proteins was evaluated using the Data Syngene program. Significant changes in the levels of protein and mRNA expression were detected, mainly in the death receptor 6 (Dr6) gene of patients suffering from cancer of the corpus and cervix uteri and ovarian cancer, which also corresponded with the level of protein Dr6. At the level of transcription, a significant increase in the expression levels of mRNA for the Gpm6B gene was detected, which led to an increase in corresponding protein in the peripheral blood of patients with gynaecological tumours against the healthy control group. This article could help to find an adequate marker for clinical application that will enable more sensitive detection of the early stages of gynaecological malignancies from the peripheral blood of patients.


Ovarian cancer Gene expression Vascular markers Death receptor 



This work was supported by the grant of the European Regional Development Fund—Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123), DIAGONKO ITMS: 26220220153 and the grant project VEGA 1/0115/14 from the Ministry of Education, Science, Research and Sport of the Slovak Republic.

Conflicts of interest



  1. 1.
    Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Pleško I., Hlava P., Chakamen S. Cancer incidence in the Slovak Republic 2007. NCR SR, NHIC. 2012; 1–138.Google Scholar
  3. 3.
    Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St CB. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007;11:539–54.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    MacFadyen JR, Haworth O, Roberston D, Hardie D, Webster MT, Morris HR, et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett. 2005;579:2569–75.PubMedCrossRefGoogle Scholar
  5. 5.
    Coneja-Garcia J, Buckanovich R, Benencia F, Courreges MC, Rubin S, Carroll R, et al. Vascular leukocytes contribute to tumor vascularization. Blood. 2005;105(2):679–81.CrossRefGoogle Scholar
  6. 6.
    Upson K, Allison KH, Reed SD, Jordan CD, Newton KM, Swisher EM, et al. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am J Obstet Gynecol. 2012;207(1):1–8.CrossRefGoogle Scholar
  7. 7.
    Combes P, Bonnet-Dupeyron MN, Gauthier-Barichard F, Schiffmann R, Bertinni E. PLP1 and GPM6B intragenic copy number analysis by MAPH in 262 patients with hypomyelinating leukodystrophies, identification of one partial triplication and two partial deletions of PLP1. Neurogenetics. 2006;7(1):31–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Lönneborg A, Jorgen A, Dumeaux V, Børresen-Dale AL. Found in transcription: gene expression and other novel blood biomarkers for the early detection of breast cancer. Expert Rev Anticancer Ther. 2009;9(8):1115–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J. 2009;23(6):1625–37.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    DeRosa DC, Ryan PJ, Okragly A, Witcher DR, Benschop RJ. Tumor-derived death receptor 6 modulates dendritic cell development. Cancer Immunol Immunother. 2008;57(6):777–87.PubMedCrossRefGoogle Scholar
  11. 11.
    Benschop R, Wei T, Na S. Tumor necrosis factor receptor superfamily member 21: TNFR-related death receptor-6, DR6. Adv Exp Med Biol. 2009;647:186–94.PubMedCrossRefGoogle Scholar
  12. 12.
    Daniels MS. Genetic testing by cancer site: uterus. Cancer J. 2012;18(4):338–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol. 2007;25:852–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Croce CM. Molecular origins of cancer, oncogenes and cancer. New England J Medicine. 2008;358:502–11.CrossRefGoogle Scholar
  15. 15.
    Yang K, Mooney C, Spahlinger G, Schuetze S, Arias-Pulido H, Verschraegen C, et al. DR6 as a diagnostic and predictive biomarker in adult sarcoma. PLoS One. 2012;7:36525.CrossRefGoogle Scholar
  16. 16.
    Fjorback AW, Müller HK, Wiborg O. Membrane glycoprotein M6B interacts with the human serotonin transporter. J Mol Neurosci. 2009;37:191–200.PubMedCrossRefGoogle Scholar
  17. 17.
    St Croix B, Rago C, Velculescu V, Romans KE, Montgomery E, Lal A, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1121–2.CrossRefGoogle Scholar
  18. 18.
    Bedkowska GE, Lawicki S, Szmitkowski M. Tumor markers useful in the diagnostic and monitoring of endometrial and cervical cancer. Postupy higieny i medycyny doświadczalnej. 2007;61:122–8.Google Scholar
  19. 19.
    Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res. 2012;18(20):1–10.CrossRefGoogle Scholar
  20. 20.
    Li F, Liu Q, Han Y, Wu B, Yin H. Sperm protein 17 is highly expressed in endometrial and cervical cancers. BMG Cancer. 2010;16(10):429.CrossRefGoogle Scholar
  21. 21.
    Wang F, Fischman D. Tumor vascular proteins: groundbreaking as potential new ovarian cancer biomarkers. Expert Review of Obstetrics and Gynecology. 2007;2(5):553–6.CrossRefGoogle Scholar
  22. 22.
    Huang GS, Gebb JS, Einstein MH, Shahabi S, Novetsky AP, Goldberg GL. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol. 2007;196(3):1–5.CrossRefGoogle Scholar
  23. 23.
    Sasarolli D, Gimothy P, Pahtak HB. Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol Ther. 2011;12(3):169–80.CrossRefGoogle Scholar
  24. 24.
    Berois N, Blanc E, Ripoche H, Mergui X, Trajtenberg F, Cantais S, et al. Cancer diagnostic, ppGalNAc-T13, a new molecular marker of bone marrow involvement in neuroblastoma. Clin Chem. 2006;52(9):1701–12.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Peter Urban
    • 1
  • Miroslava Bilecova Rabajdova
    • 1
  • Jan Varga
    • 2
  • Peter Kruzliak
    • 3
  • Viera Fialkovicova
    • 2
  • Eva Durovcova
    • 1
  • Maria Marekova
    • 1
  1. 1.Department of Medical and Clinical Biochemistry, Faculty of MedicinePavol Jozef Safarik UniversityKosiceSlovak Republic
  2. 2.2nd Department of Gynaecology and Obstetrics, Faculty of MedicinePavol Jozef Safarik UniversityKosiceSlovak Republic
  3. 3.International Clinical Research CenterSt. Anne’s University Hospital and Masaryk UniversityBrnoCzech Republic

Personalised recommendations